Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction

This publication has 24 references indexed in Scilit:

• Albiglutide
  Drugs of the Future, 2010
• Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?
  British Journal of Pharmacology, 2009
• Energy metabolism in heart failure and remodelling
  Cardiovascular Research, 2008
• Reproducibility of Peak Oxygen Uptake and Other Cardiopulmonary Exercise Testing Parameters in Patients With Heart Failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing)
  The American Journal of Cardiology, 2008
• Recruitment of Compensatory Pathways to Sustain Oxidative Flux With Reduced Carnitine Palmitoyltransferase I Activity Characterizes Inefficiency in Energy Metabolism in Hypertrophied Hearts
  Circulation, 2007
• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts
  The Journal of Pharmacology and Experimental Therapeutics, 2006
• Impact of reversible trapping of tracer and the presence of blood metabolites on measurements of myocardial glucose utilization performed by PET and 18F-fluorodeoxyglucose using the Patlak method
  Nuclear Medicine and Biology, 2004
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion
  Circulation, 2004
• Improvement in the mechanical efficiency of walking: An explanation for the “placebo effect” seen during repeated exercise testing of patients with heart failure
  American Heart Journal, 1998
• Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan
  American Heart Journal, 1992